UNSPSC 51413404: Endralazine mesilate or mesylate

This classification denotes a vasodilating agent with the molecular formula C14H15N5O.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 333M5986I5, chemically known as 6-benzoyl-5,6,7,8-tetrahydropyrido(4,3-c)pyridazin-3(2h)-one hydrazone monomethanesulfonate but more generally known as endralazine mesilate, which bears US NIH Compound Identifier 47607. European Medicines Agency schedules Endralazine mesilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01886MIG.

UNSPSC 51413404 Endralazine mesilate or mesylate is a Commodity code covering specific pharmaceutical active ingredients used in state and local emergency medical services and health benefit programs. Recent activity shows state and local governments procuring advanced life support medications and generic pharmaceuticals through sealed competitive bidding, cooperative purchasing alliances, and exploratory RFIs aimed at direct manufacturer relationships. The City of Tampa Fire Rescue and the Texas Health and Human Services Commission represent the issuing-body mix — municipal fire departments and state health agencies — with cooperative purchasing vehicles such as the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) extending reach across multiple jurisdictions and authorized wholesale distribution channels.

The code sees activity in Florida, Texas, and Minnesota, with MMCAP's multi-state reach extending to Oregon. Recent representative opportunities include the City of Tampa's sealed bid for Advanced Life Support Medications (IFB No. 26P00188, due April 8, 2026, estimated value $40,000) supplying epinephrine, labetalol, adenosine, and diltiazem vials to emergency medical personnel; the Texas Health and Human Services Commission's RFI (HHS0017013, posted April 3, 2026) exploring direct-to-manufacturer prescription relationships outside traditional PBM and wholesaler channels; and MMCAP's RFP for Generic Multi Source Pharmaceuticals and OTC Products (S1070000015802, due March 26, 2026) seeking manufacturers to supply through three authorized wholesalers for state and local facilities. The Tampa bid includes a 5 percent SLBE bid discount capped at $10,000 and requires Safety Data Sheets compliant with OSHA standards and WCAG 2.2 Level AA accessibility conformance. MMCAP's RFP emphasizes cGMP and Drug Supply Chain Security Act compliance, requires $5 million commercial general liability coverage, and applies performance penalties of $200 to $1,500 per violation.